Clinical trials: Immune System Function
- Condition Immune System Function
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Asthma
Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.
Comparison of two asthma treatments by lung function measures.
- Trial name
- NCT00169546
- Testing
- Salmeterol/fluticasone propionate, Fluticasone propionate
- Where
- 2 sites in New Zealand, United Kingdom
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Infantile Colics, Constipation
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete
This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional…
- Conditions
- Infantile Colics, Constipation, Infantile Diarrhea, Atopic Dermatitis
- Trial name
- NCT07444008
- Testing
- BioAmicus Complete
- Where
- Russia
- Volunteers
- 140 people
- Sponsor
- NovoNatum Ltd
Asthma
Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients
A single intravenous injection of zileuton (150 or 300 mg) will be administered to patients with stable asthma. The goals will be to determine if zileuton i.v.
- Trial name
- NCT00534625
- Testing
- zileuton
- Volunteers
- 36 people
- Sponsor
- Critical Therapeutics
Asthma
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
The aim of the study is to compare the effects of ciclesonide inhaled at one dose level twice daily versus fluticasone propionate inhaled at one dose level twice daily versus placebo, on short-term lower leg growth in prepubertal…
- Trial name
- NCT00163371
- Testing
- Ciclesonide
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Rhinitis, Allergic, Perennial
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in adolescents and adults 12 to 65 years of…
- Trial name
- NCT00116818
- Testing
- GW685698X aqueous nasal spray
- Where
- 2 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Osteoarthritis, Avascular Necrosis
Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects
primary endpoint of this Study is maintenance of "at least good clinical status" for a period of 10 years following initial implantation among Cormet procedures enrolled inthe pre-market IDE.
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
- Trial name
- PAS:IDE (NCT00721994)
- Testing
- Cormet Hip Resurfacing System
- Where
- 5 sites in United States
- Volunteers
- 231 people
- Sponsor
- Corin
Asthma in Children
Proof-of-concept of the Measurement of Lung Function Using the Relaxed Expiratory Occlusion Monitor (REOM)
(i) To validate the inversed occlusion technique by comparing the results of resistance obtained on the relaxed expiratory occlusion monitor (REOM) with the resistance obtained with respiratory oscillometry (OSC) measurements on…
- Trial name
- NCT04903145
- Testing
- REOM
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Thorasys Thoracic Medical Systems Inc.
Poor Thymic Function, Immunodeficiency
Expanded Access Protocol Thymus Transplantation
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation.
- Conditions
- Poor Thymic Function, Immunodeficiency, Athymia, Immunoreconstitution
- Trial name
- NCT02274662
- Testing
- Cultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
- Volunteers
- 11 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Rhinitis, Allergic, Perennial
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age…
- Trial name
- NCT00116883
- Testing
- GW685698X aqueous nasal spray
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss…
- Trial name
- PELISTAD-EX2 (NCT05983068)
- Testing
- dupilumab
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy.
- Trial name
- SPHINX (NCT06943469)
- Testing
- Test formula, Control formula
- Where
- 25 sites in Belgium, France and 3 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
This study will be conducted to observe the disease activity change of Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARD) plus anti-tumour necrosis factor (anti-TNF) from baseline to 6 months compared with cDMARDs, as…
- Trial name
- HUMAN (NCT03264703)
- Where
- 15 sites in South Korea
- Volunteers
- 212 people
- Sponsor
- Eisai Korea Inc.
Type 1 Diabetes Mellitus
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell…
- Trial name
- T1D OBTAIN (NCT06812988)
- Testing
- Brivekimig
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Hereditary Angioedema (HAE)
A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals.
- Trial name
- AHAE (NCT07293364)
- Testing
- Technochrom C1-INH Kit
- Where
- Algeria
- Volunteers
- 514 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on…
- Trial name
- FABULINUS (NCT06111586)
- Testing
- Frexalimab, Insulin
- Where
- 79 sites in United States, Austria and 14 more
- Volunteers
- 197 people
- Sponsor
- Sanofi